Integrating Various Sensor Readings from MySignals into a Standalone Mobile Health App
Permanent lenke
https://hdl.handle.net/10037/22320Dato
2021-05-22Type
Master thesisMastergradsoppgave
Forfatter
Koirala, MadhuSammendrag
This project integrates various health parameters Temperature, Heart Rate, Pulse Rate, Blood Pressure, Respiration Rate, ECG, EMG, GSR, Spirometry values, Snore, Blood Sugar, Body Positions and Weight measured through wired and wireless sensors, into a standalone mobile health app. It shows Health Status of the user based on these parameters, and displays the values in different colors for normal and abnormal readings. Users can plot graphs of their selected parameters to enhance their understanding and how one parameter can affect the other. The project also presents a deeper analysis of Glucose and Heart Rate by calculating Glucose Variability and Heart Rate Variability. These analyses give patients and doctors more insightful information about their health and may act as a guidance to decide a better treatment regimen.It can also count the number of steps of patients for monitoring their activity and send SMS to patients and caregivers if the Health Status is abnormal.
Forlag
UiT Norges arktiske universitetUiT The Arctic University of Norway
Metadata
Vis full innførselSamlinger
Copyright 2021 The Author(s)
Følgende lisensfil er knyttet til denne innførselen:
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Relaterte innførsler
Viser innførsler relatert til tittel, forfatter og emneord.
-
Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee
Jokstad, Asbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-27)Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems. The Cochrane Collaboration SRs are considered as the highest standard in evidence-based health care resources. All SRs completed during the last 5 years (2013–2017) under the management of the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included in the Oral Health ... -
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ... -
The Use of eHealth and Provider-Based Health Services by Patients with Diabetes Mellitus: Protocol for a Cross-Sectional Study
Hansen, Anne Helen; Bradway, Meghan; Brož, Jan; Claudi, Tor; Henriksen, Øystein; Wangberg, Silje C; Årsand, Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-31)<b>Background:</b> The prevalence of diabetes and the use of electronic health (eHealth) resources are increasing. People with diabetes need frequent monitoring and follow-up of health parameters, and eHealth services can be of great significance in this regard. However, little is known about the extent to which different kinds of eHealth tools are used, and how the use of eHealth is associated ...